norbuprenorphine has been researched along with Opioid-Related Disorders in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Bal, C; Danışman, M; İspir, GZ; Kaya-Akyüzlü, D; Oğur, B; Özkan-Kotiloğlu, S | 1 |
| Berquist, MD; Brents, LK; Coward, LU; Gorman, GS; Parks, BJ; Salazar, P; Tobacyk, J | 1 |
| Bastian, JR; Caritis, SN; Chaphekar, N; Chen, H; Shaik, IH; Venkataramanan, R; Zhang, H; Zhao, W | 1 |
| Booth, K; Francis-Fath, S; Warrington, GS; Warrington, JS | 1 |
| Darke, S; Duflou, J; Farrell, M; Lappin, J; Larance, B | 1 |
| Asatryan, A; Geoffroy, P; Kort, J; Kosloski, MP; Liu, W; Zhao, W | 1 |
| Donroe, JH; Holt, SR; O'Connor, PG; Sukumar, N; Tetrault, JM | 1 |
| Accurso, AJ; Lee, JD; McNeely, J | 1 |
| Baillie, S; Bell, J; Bogdanowicz, K; Knight, A; Reed, K; Strang, J | 1 |
| Cavallo, DA; Donroe, JH; Holt, SR; Tetrault, JM | 1 |
| Häkkinen, M; Kriikku, P; Ojanperä, I | 1 |
| Alund, AW; Brents, LK; Cabanlong, CV; Caperton, CO; Fantegrossi, WE; Griffin, BA; Martins, BS; Moran, JH; Owens, SM; Patton, AL; Russell, LN; Urquhart, KR; Wilson, CD; Zita, MD | 1 |
| Dong, R; Gray, F; Jiang, J; Laffont, CM; Lang, L; Learned, SM; Li, D; Liu, Y; Liu, Z; Wang, H; Young, M | 1 |
| Fudala, PJ; Gomeni, R; Greenwald, MK; Heidbreder, C; Nasser, AF; Zheng, B | 1 |
| DInh, AT; Fiellin, DA; Fiellin, LE; Lruie, BS; McCance-Katz, EF; Moody, DE; Tetrault, JM | 1 |
| Marin, SJ; McMillin, GA | 1 |
| Albayaty, M; Johnsson, M; Linden, M; Olsson, H; Strandgården, K; Tiberg, F | 1 |
| Baillie, S; Beavan, P; Bell, J; Bogdanowicz, K; Keen, J; Knight, A; Reed, K; Strang, J; van der Waal, R | 1 |
| Concheiro, M; Huestis, MA; Shakleya, DM | 1 |
| Concheiro, M; Huestis, MA; Johnson, RE; Jones, H; Shakleya, DM | 1 |
| Druid, H; Kronstrand, R; Roman, M; Seldén, T | 1 |
| Choo, R; Concheiro, M; Huestis, MA; Johnson, RE; Jones, HE | 1 |
| Bigelow, GE; Moody, DE; Stoller, KB; Strain, EC; Walsh, SL | 1 |
| Chauhan, M; George, C; George, S | 1 |
| Huestis, MA; Kacinko, SL; Shakleya, DM | 1 |
| Kintz, P; Ludes, B; Tracqui, A | 1 |
7 trial(s) available for norbuprenorphine and Opioid-Related Disorders
| Article | Year |
|---|---|
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Methadone; Middle Aged; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Young Adult | 2017 |
Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine
.
Topics: Administration, Sublingual; Analgesics, Opioid; Biological Availability; Biotransformation; Buprenorphine; Drug Compounding; Freeze Drying; Humans; Lung; Opiate Substitution Treatment; Opioid-Related Disorders; Respiration; Respiratory Insufficiency; Risk Factors; Solubility; Tablets; Treatment Outcome | 2018 |
Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Area Under Curve; Asian People; Biological Availability; Buprenorphine; Female; Humans; Male; Naloxone; Opioid-Related Disorders; Tablets | 2019 |
A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Injections; Injections, Subcutaneous; Male; Models, Biological; Opioid-Related Disorders; Receptors, Opioid, mu | 2014 |
Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
Topics: Administration, Sublingual; Adult; Biological Availability; Buprenorphine; Delayed-Action Preparations; Drug Monitoring; Female; Healthy Volunteers; Humans; Injections, Subcutaneous; Male; Middle Aged; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2017 |
Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Routes; Female; Humans; Opiate Substitution Treatment; Opioid-Related Disorders; Tablets | 2017 |
Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.
Topics: Area Under Curve; Buprenorphine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Narcotic Antagonists; Opioid-Related Disorders; Postpartum Period; Pregnancy; Saliva; Sweat | 2011 |
19 other study(ies) available for norbuprenorphine and Opioid-Related Disorders
| Article | Year |
|---|---|
OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder.
Topics: Buprenorphine; Chromatography, Liquid; Humans; Opioid-Related Disorders; Receptors, Opioid, delta; Tandem Mass Spectrometry | 2023 |
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Female; Humans; Infant, Newborn; Male; Neonatal Abstinence Syndrome; Opioid-Related Disorders; Pregnancy; Rats; Rats, Long-Evans; Receptors, Opioid, mu | 2023 |
Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.
Topics: Adult; Buprenorphine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Glucuronosyltransferase; Humans; Longitudinal Studies; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Postpartum Period; Pregnancy; Pregnancy Trimesters; Young Adult | 2020 |
Use of urinary naloxone levels in a single provider practice: a case study.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Detection | 2020 |
Characteristics and circumstances of death related to buprenorphine toxicity in Australia.
Topics: Adult; Aged; Analgesics, Opioid; Australia; Buprenorphine; Cause of Death; Central Nervous System Stimulants; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Opiate Overdose; Opioid-Related Disorders | 2021 |
Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice.
Topics: Buprenorphine; Humans; Opioid-Related Disorders; Retrospective Studies | 2017 |
High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Humans; Male; Medication Adherence; Middle Aged; New York City; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; Urinalysis | 2017 |
Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Drug Contamination; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Substance Abuse Detection | 2018 |
High buprenorphine-related mortality is persistent in Finland.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Blood Alcohol Content; Buprenorphine; Chromatography, Liquid; Drug Overdose; Female; Finland; Humans; Male; Mass Spectrometry; Middle Aged; Naloxone; Opioid-Related Disorders; Sex Distribution; Substance Abuse, Intravenous; Young Adult | 2018 |
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.
Topics: Animals; Animals, Newborn; Buprenorphine; Female; Fetus; Opioid-Related Disorders; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Risk; Substance Withdrawal Syndrome | 2019 |
The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection.
Topics: Adult; Anti-HIV Agents; Buprenorphine; Cocaine; Cocaine-Related Disorders; Drug Interactions; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Stereoisomerism; Time Factors | 2015 |
Quantitation of Total Buprenorphine and Norbuprenorphine in Meconium by LC-MS/MS.
Topics: Analgesics, Opioid; Buprenorphine; Chromatography, Liquid; Female; Humans; Infant, Newborn; Meconium; Opioid-Related Disorders; Pregnancy; Tandem Mass Spectrometry | 2016 |
Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry.
Topics: Buprenorphine; Chromatography, Liquid; Female; Forensic Toxicology; Glucuronides; Humans; Narcotic Antagonists; Opioid-Related Disorders; Pregnancy; Tandem Mass Spectrometry; Umbilical Cord | 2009 |
Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women.
Topics: Buprenorphine; Chromatography, Liquid; Female; Fetal Blood; Glucuronides; Humans; Linear Models; Narcotic Antagonists; Opioid-Related Disorders; Pregnancy; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2010 |
LC-MS-MS analysis of buprenorphine and norbuprenorphine in whole blood from suspected drug users.
Topics: Buprenorphine; Chromatography, Liquid; Female; Forensic Toxicology; Humans; Male; Narcotics; Opioid-Related Disorders; Substance Abuse Detection; Tandem Mass Spectrometry | 2011 |
Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
Topics: Area Under Curve; Biological Availability; Buprenorphine; Chemistry, Pharmaceutical; Female; Humans; Male; Opioid-Related Disorders | 2004 |
The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols.
Topics: Buprenorphine; Creatinine; Dose-Response Relationship, Drug; Female; Forensic Medicine; Gas Chromatography-Mass Spectrometry; Humans; Male; Narcotic Antagonists; Opioid-Related Disorders; Regression Analysis; Reproducibility of Results | 2004 |
Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.
Topics: Buprenorphine; Calibration; Chromatography, Liquid; Female; Glucuronides; Humans; Infant; Meconium; Mothers; Opioid-Related Disorders; Pregnancy; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2008 |
Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.
Topics: Adolescent; Adult; Bile; Buprenorphine; Drug Interactions; Female; France; Gas Chromatography-Mass Spectrometry; Hair; Humans; Male; Middle Aged; Narcotic Antagonists; Opioid-Related Disorders; Survival Analysis; Tissue Distribution | 1998 |